QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:INGN

Inogen (INGN) Stock Forecast, Price & News

$10.68
-0.48 (-4.30%)
(As of 05:22 PM ET)
Compare
Today's Range
$10.63
$11.13
50-Day Range
$10.01
$13.86
52-Week Range
$9.88
$32.01
Volume
306,095 shs
Average Volume
270,370 shs
Market Capitalization
$246.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00

Inogen MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
124.7% Upside
$24.00 Price Target
Short Interest
Bearish
5.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.91mentions of Inogen in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.16) to ($1.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

363rd out of 981 stocks

Surgical Appliances & Supplies Industry

9th out of 18 stocks


INGN stock logo

About Inogen (NASDAQ:INGN) Stock

Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.

Receive INGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter.

INGN Stock News Headlines

Will the Current Downturn Affect Inogen (INGN)?
Pentagon Consultant—Here's how Biden Wins Landslide Re-election
—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,
Inogen (NASDAQ:INGN) Downgraded by StockNews.com to Sell
Inogen (NASDAQ:INGN) Upgraded to "Hold" at StockNews.com
BREAKING: The truth about war with China
Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.
Inogen (INGN) Scheduled to Post Earnings on Thursday
Inogen (NASDAQ:INGN) Cut to "Sell" at StockNews.com
Inogen (NASDAQ:INGN) Rating Lowered to Sell at StockNews.com
A Look At The Fair Value Of Inogen, Inc. (NASDAQ:INGN)
Inogen (NASDAQ:INGN) Raised to "Hold" at StockNews.com
Inogen (NASDAQ:INGN) Stock Rating Lowered by StockNews.com
See More Headlines

INGN Price History

INGN Company Calendar

Last Earnings
5/04/2023
Today
6/08/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INGN
Fax
N/A
Employees
1,026
Year Founded
2001

Price Target and Rating

Average Stock Price Forecast
$24.00
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+124.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-83,770,000.00
Pretax Margin
-24.24%

Debt

Sales & Book Value

Annual Sales
$369.02 million
Book Value
$12.98 per share

Miscellaneous

Free Float
22,973,000
Market Cap
$246.93 million
Optionable
Optionable
Beta
1.02

Social Links


Key Executives

  • Nabil Shabshab
    President, Chief Executive Officer & Director
  • Kristin A. Caltrider
    Chief Financial Officer, Treasurer & EVP
  • Stanislav Glezer
    Chief Technology Officer & Executive VP
  • George J. Parr
    Chief Commercial Officer & Executive VP
  • Jason Somer
    Secretary, Executive VP & General Counsel













INGN Stock - Frequently Asked Questions

Should I buy or sell Inogen stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" INGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View INGN analyst ratings
or view top-rated stocks.

What is Inogen's stock price forecast for 2023?

3 Wall Street analysts have issued 12-month price objectives for Inogen's shares. Their INGN share price forecasts range from $22.00 to $26.00. On average, they predict the company's stock price to reach $24.00 in the next year. This suggests a possible upside of 115.1% from the stock's current price.
View analysts price targets for INGN
or view top-rated stocks among Wall Street analysts.

How have INGN shares performed in 2023?

Inogen's stock was trading at $19.71 on January 1st, 2023. Since then, INGN shares have decreased by 43.4% and is now trading at $11.16.
View the best growth stocks for 2023 here
.

When is Inogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our INGN earnings forecast
.

How were Inogen's earnings last quarter?

Inogen, Inc. (NASDAQ:INGN) released its quarterly earnings data on Thursday, May, 4th. The medical technology company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.14. The medical technology company earned $72.16 million during the quarter, compared to the consensus estimate of $74.68 million. Inogen had a negative net margin of 24.36% and a negative trailing twelve-month return on equity of 11.06%. The company's quarterly revenue was down 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.38) earnings per share.

What is Scott Wilkinson's approval rating as Inogen's CEO?

70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Inogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

What is Inogen's stock symbol?

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Who are Inogen's major shareholders?

Inogen's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (17.20%), Brown Capital Management LLC (9.55%), Fred Alger Management LLC (4.86%), State Street Corp (4.65%), Dimensional Fund Advisors LP (3.72%) and Geode Capital Management LLC (1.95%). Insiders that own company stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Holdings A/S Novo, Ray Benjamin M Anderson and Raymond Huggenberger.
View institutional ownership trends
.

How do I buy shares of Inogen?

Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inogen's stock price today?

One share of INGN stock can currently be purchased for approximately $11.16.

How much money does Inogen make?

Inogen (NASDAQ:INGN) has a market capitalization of $258.03 million and generates $369.02 million in revenue each year. The medical technology company earns $-83,770,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis.

How many employees does Inogen have?

The company employs 1,026 workers across the globe.

How can I contact Inogen?

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The official website for the company is www.inogen.com. The medical technology company can be reached via phone at (805) 562-0500 or via email at mpigeon@inogen.net.

This page (NASDAQ:INGN) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -